Xeljanz and XeljanzXR
Xeljanz is a medication marketed by Pfizer prescribed to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Xeljanz works by suppressing a patient’s immune system. Xeljanz has been associated with an increased risk of blood clotting problems such as pulmonary embolism, deep vein thrombosis and, in some cases, death.
In February 2021, the FDA reported on clinical trials showing an association between Xeljanz and serious cardiac problems and cancer. In September 2021, the FDA issued a Drug Safety Communication indicating, in part, “We have concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots and death with the arthritis and ulcerative colitis medicines Xeljanz and XeljanzXR (tofacitinib).”